BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 766.21M | 874.57M | 776.13M | 825.41M | 745.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 766.21M | 874.57M | 776.13M | 825.41M | 745.15M |
| Cost of Revenue | 373.80M | 348.91M | 549.56M | 311.40M | 310.29M |
| Gross Profit | 392.41M | 525.65M | 226.57M | 514.01M | 434.86M |
| SG&A Expenses | 249.98M | 324.16M | 268.42M | 232.28M | 206.12M |
| Depreciation & Amortization | 4.48M | 4.85M | 4.85M | 4.85M | 4.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 628.26M | 677.92M | 822.83M | 548.52M | 521.25M |
| Operating Income | 137.95M | 196.64M | -46.69M | 276.89M | 223.89M |
| Income Before Tax | 141.20M | -27.15M | -26.32M | 297.87M | 238.09M |
| Income Tax Expenses | 35.68M | 19.42M | 4.42M | 57.34M | 52.40M |
| Earnings from Continuing Operations | 105.53M | -46.57M | -30.74M | 240.53M | 185.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.53M | -46.57M | -30.74M | 240.53M | 185.69M |
| EBIT | 137.95M | 196.64M | -46.69M | 276.89M | 223.89M |
| EBITDA | 154.36M | 209.68M | -28.21M | 295.45M | 245.96M |
| EPS Basic | 0.55 | -0.24 | -0.16 | 1.25 | 0.97 |
| Normalized Basic EPS | 0.49 | 0.70 | -0.09 | 0.97 | 0.78 |
| EPS Diluted | 0.53 | -0.24 | -0.16 | 1.23 | 0.95 |
| Normalized Diluted EPS | 0.47 | 0.70 | -0.09 | 0.94 | 0.76 |
| Average Basic Shares Outstanding | 192.50M | 192.23M | 192.03M | 191.91M | 190.97M |
| Average Diluted Shares Outstanding | 197.67M | 192.23M | 192.03M | 197.09M | 196.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |